Swiss Biotech Day shows great biopharma ambitions
The Swiss biopharmaceutical industry is on the verge of record growth: This was demonstrated at the live Swiss Biotech Day in Basel.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
EuropaBio lobbies for better Orphan Drug rules
/in News/by Thomas GabrielczykEuropaBio has responded to the European Commissions public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.
Cardior bags 64m in Series B Financing
/in News/by Thomas GabrielczykCardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure.
ERS Genomics and Cellular Engineering Technologies collaborating
/in News/by Thomas GabrielczykERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.
Visus Therapeutics cashes in 20m from LSP
/in News/by Thomas GabrielczykVisus Therapeutics has baged a 20m stock financing to advance development of Brimochol for presbyopia
British drug developer Mission Therapeutics plc earns $20m milestone
/in News/by Thomas GabrielczykBritish drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.
Spectricity raises 14m in Series B round
/in News/by Thomas GabrielczykBelgian semiconductor specialist Spectricity BV has baged 14m to speed up the development of mobile hyperspectral sensors for medical applications.
Abcam to acquire BioVision for $340m
/in News/by Thomas GabrielczykLife sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.
Byondis and Glycotope merge platforms to target carbohydrates
/in News/by Thomas GabrielczykCancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement.